Etude de la dynamique de la macrofaune du sol sous culture de deux variétés de patate douce (Ipomea batatas) avec utilisation de différents modes de désherbage

Les communautés de la macrofaune du sol sous culture de deux variétés de patate douce (BF 11 et Ejumula 2) ont été inventoriées huit semaines après le repiquage des boutures. Les expérimentations ont été conduites en 2014 sur des parcelles du Centre de Formation et de Recherches Environnementales et Agricoles et de Formation de Kamboinsé de l’Institut de l’Environnement et de Recherches Agricoles (INERA). L’objectif de cette étude était d’identifier les différentes espèces de la faune du sol et de déterminer l’influence des différentes pratiques agricoles sur la faune du sol. Les termites ont été échantillonnés par la méthode des monolithes et par transect ; les vers de terre ont été échantillonnés uniquement par monolithes. Au total, quinze (15) espèces d’insectes et deux (02) espèces de vers de terre ont été enregistrées sous les traitements de la variété F0. Pour les insectes, les espèces identifiées sont : Microtermes pusillus, Feronia sp, Capsus sp, Amara sp, Amara auliae, Philontus marginatus, Dromius sp, Dromius quadrimaculatus, Xestobium sp, Pachycondyla analis, Paederus sp, Trinervitermes sp, Monyomorium abyssinicumi, Dyschirius globusus, Amitermes stephensoni. Les vers de terre identifiés sont Milsonia inermis et Dichogaster affininis. Les traitements sans désherbage ou désherbage tardif (après la huitième semaine) ont connu une meilleure installation de la macrofaune du sol. Les termites ont été les organismes favorisés dans les cas d’absence totale de désherbage. Le type de variété de patate douce n’a pas eu d’effet sur les communautés des la macrofaune du sol.© 2015 International Formulae Group. All rights reserved.Mots clés: Patate douce, macrofaune du sol, désherbage, traitementEnglish Title: Study of the dynamics of soil macrofauna under cultivation of two varieties of sweet potato (Ipomoea batatas) using different modes of weedingEnglish AbstractThe communities of soil macrofauna under cultivation of two varieties of sweet potato (BF 11 and Ejumula 2) were surveyed eight weeks after cuttings transplanting. The experiments were conducted in 2014 on plots of the Training Centre for Environmental Research and Agricultural of Kamboinsé, Training Institute for the Environment and Agricultural Research (INERA). The objective of this study was to identify the different species of soil fauna and determine the influence of different agricultural practices on soil fauna. The termites were sampled by the monoliths and transect method; earthworms were sampled only by monoliths. Fifteen (15) species of insects and two (02) species of earthworm have been registered in the treatment of F0 variety. For insects, the species identified are: Microtermes pusillus, Feronia sp Capsus sp sp Amara, Amara auliae, Philontus marginatus, Dromius sp Dromius quadrimaculatus Xestobium sp Pachycondyla analis, Paederus sp sp Trinervitermes, Monyomorium abyssinicumi, Dyschirius globosus , Amitermes stephensoni. Earthworms identified are Milsonia inermis and Dichogaster affininis. The treatment without weeding or late weeding (after the eighth week) had a better installation of the soil macrofauna. Termites were the favored organisms in the event of total absence of weeding. The type of variety of sweet potato hadn’t any effect on the communities of soil macrofauna.© 2015 International Formulae Group. All rights reserved.Keywords: Sweet potato, soil macrofauna, weeding, treatmen

SARS-CoV-2 infection and antibody seroprevalence in routine surveillance patients, healthcare workers and general population in Kita region, Mali: an observational study 2020–2021

Objective: To estimate the degree of SARS-CoV-2 transmission among healthcare workers (HCWs) and general population in Kita region of Mali. Design: Routine surveillance in 12 health facilities, HCWs serosurvey in five health facilities and community serosurvey in 16 villages in or near Kita town, Mali. Setting: Kita region, western Mali; local health centres around the central (regional) referral health centre. Participants: Patients in routine surveillance, HCWs in local health centres and community members of all ages in populations associated with study health centres. Main outcome measures: Seropositivity of ELISA test detecting SARS-CoV-2-specific total antibodies and real-time RT-PCR confirmed SARS-CoV-2 infection. Results: From 2392 routine surveillance samples, 68 (2.8%, 95% CI: 2.2% to 3.6%) tested positive for SARS-CoV-2 by RT-PCR. The monthly positivity rate was 0% in June–August 2020 and gradually increased to 6% by December 2020 and 6.2% by January 2021, then declined to 5.5%, 3.3%, 3.6% and 0.8% in February, March, April and May 2021, respectively. From 397 serum samples collected from 113 HCWs, 175 (44.1%, 95% CI: 39.1% to 49.1%) were positive for SARS-CoV-2 antibodies. The monthly seroprevalence was around 10% from September to November 2020 and increased to over 40% from December 2020 to May 2021. For community serosurvey in December 2020, overall seroprevalence of SARS-CoV-2 antibodies was 27.7%. The highest age-stratified seroprevalence was observed in participants aged 60–69 years (45.5%, 95% CI: 32.3% to 58.6%). The lowest was in children aged 0–9 years (14.0%, 95% CI: 7.4% to 20.6%). Conclusions: SARS-CoV-2 in rural Mali is much more widespread than assumed by national testing data and particularly in the older population and frontline HCWs. The observation is contrary to the widely expressed view, based on limited data, that COVID-19 infection rates were lower in 2020–2021 in West Africa than in other settings

Meningococcal carriage within households in the African meningitis belt: A longitudinal pilot study.

OBJECTIVES: Carriers of Neisseria meningitidis are a key source of transmission. In the African meningitis belt, where risk of meningococcal disease is highest, a greater understanding of meningococcal carriage dynamics is needed. METHODS: We randomly selected an age-stratified sample of 400 residents from 116 households in Bamako, Mali, and collected pharyngeal swabs in May 2010. A month later, we enrolled all 202 residents of 20 of these households (6 with known carriers) and collected swabs monthly for 6 months prior to MenAfriVac vaccine introduction and returned 10 months later to collect swabs monthly for 3 months. We used standard bacteriological methods to identify N. meningitidis carriers and fit hidden Markov models to assess acquisition and clearance overall and by sex and age. RESULTS: During the cross-sectional study 5.0% of individuals (20/400) were carriers. During the longitudinal study, 73 carriage events were identified from 1422 swabs analyzed, and 16.3% of individuals (33/202) were identified as carriers at least once. The majority of isolates were non-groupable; no serogroup A carriers were identified. CONCLUSIONS: Our results suggest that the duration of carriage with any N. meningitidis averages 2.9 months and that males and children acquire and lose carriage more frequently in an urban setting in Mali. Our study informed the design of a larger study implemented in seven countries of the African meningitis belt

Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial

SummaryBackgroundThe 2014 west African Zaire Ebola virus epidemic prompted worldwide partners to accelerate clinical development of replication-defective chimpanzee adenovirus 3 vector vaccine expressing Zaire Ebola virus glycoprotein (ChAd3-EBO-Z). We aimed to investigate the safety, tolerability, and immunogenicity of ChAd3-EBO-Z in Malian and US adults, and assess the effect of boosting of Malians with modified vaccinia Ankara expressing Zaire Ebola virus glycoprotein and other filovirus antigens (MVA-BN-Filo).MethodsIn the phase 1, single-blind, randomised trial of ChAd3-EBO-Z in the USA, we recruited adults aged 18–65 years from the University of Maryland medical community and the Baltimore community. In the phase 1b, open-label and double-blind, dose-escalation trial of ChAd3-EBO-Z in Mali, we recruited adults 18–50 years of age from six hospitals and health centres in Bamako (Mali), some of whom were also eligible for a nested, randomised, double-blind, placebo-controlled trial of MVA-BN-Filo. For randomised segments of the Malian trial and for the US trial, we randomly allocated participants (1:1; block size of six [Malian] or four [US]; ARB produced computer-generated randomisation lists; clinical staff did randomisation) to different single doses of intramuscular immunisation with ChAd3-EBO-Z: Malians received 1 × 1010 viral particle units (pu), 2·5 × 1010 pu, 5 × 1010 pu, or 1 × 1011 pu; US participants received 1 × 1010 pu or 1 × 1011 pu. We randomly allocated Malians in the nested trial (1:1) to receive a single dose of 2 × 108 plaque-forming units of MVA-BN-Filo or saline placebo. In the double-blind segments of the Malian trial, investigators, clinical staff, participants, and immunology laboratory staff were masked, but the study pharmacist (MK), vaccine administrator, and study statistician (ARB) were unmasked. In the US trial, investigators were not masked, but participants were. Analyses were per protocol. The primary outcome was safety, measured with occurrence of adverse events for 7 days after vaccination. Both trials are registered with ClinicalTrials.gov, numbers NCT02231866 (US) and NCT02267109 (Malian).FindingsBetween Oct 8, 2014, and Feb 16, 2015, we randomly allocated 91 participants in Mali (ten [11%] to 1 × 1010 pu, 35 [38%] to 2·5 × 1010 pu, 35 [38%] to 5 × 1010 pu, and 11 [12%] to 1 × 1011 pu) and 20 in the USA (ten [50%] to 1 × 1010 pu and ten [50%] to 1 × 1011 pu), and boosted 52 Malians with MVA-BN-Filo (27 [52%]) or saline (25 [48%]). We identified no safety concerns with either vaccine: seven (8%) of 91 participants in Mali (five [5%] received 5 × 1010 and two [2%] received 1 × 1011 pu) and four (20%) of 20 in the USA (all received 1 × 1011 pu) given ChAd3-EBO-Z had fever lasting for less than 24 h, and 15 (56%) of 27 Malians boosted with MVA-BN-Filo had injection-site pain or tenderness.Interpretation1 × 1011 pu single-dose ChAd3-EBO-Z could suffice for phase 3 efficacy trials of ring-vaccination containment needing short-term, high-level protection to interrupt transmission. MVA-BN-Filo boosting, although a complex regimen, could confer long-lived protection if needed (eg, for health-care workers).FundingWellcome Trust, Medical Research Council UK, Department for International Development UK, National Cancer Institute, Frederick National Laboratory for Cancer Research, Federal Funds from National Institute of Allergy and Infectious Diseases

Correction: A Seroepidemiological Study of Serogroup A Meningococcal Infection in the African Meningitis Belt.

[This corrects the article DOI: 10.1371/journal.pone.0147928.]

Towards Resilient Agriculture to Hostile Climate Change in the Sahel Region: A Case Study of Machine Learning-Based Weather Prediction in Senegal

To ensure continued food security and economic development in Africa, it is very important to address and adapt to climate change. Excessive dependence on rainfed agricultural production makes Africa more vulnerable to climate change effects. Weather information and services are essential for farmers to more effectively survive the increasing occurrence of extreme weather events due to climate change. Weather information is important for resource management in agricultural production and helps farmers plan their farming activities in advance. Machine Learning is one of the technologies used in agriculture for weather forecasting and crop disease detection among others. The objective of this study is to develop Machine Learning-based models adapted to the context of daily weather forecasting for Rainfall, Relative Humidity, and Maximum and Minimum Temperature in Senegal. In this study, we made a comparison of ten Machine Learning Regressors with our Ensemble Model. These models were evaluated based on Mean Absolute Error, Mean Squared Error, Root Mean Squared Error and Coefficient of Determination. The results show that the Ensemble Model performs better than the ten base models. The Ensemble Model results for each parameter are as follows; Relative Humidity: Mean Absolute Error was 4.0126, Mean Squared Error was 29.9885, Root Mean Squared Error was 5.4428 and Coefficient of Determination was 0.9335. For Minimum Temperature: Mean Absolute Error was 0.7908, Mean Squared Error was 1.1329, Root Mean Squared Error was 1.0515 and Coefficient of Determination was 0.9018. For Maximum Temperature: Mean Absolute Error was 1.2515, Mean Squared Error was 2.8038, Root Mean Squared Error was 1.6591 and Coefficient of Determination was 0.8205. For Rainfall: Mean Absolute Error was 0.2142, Mean Squared Error was 0.1681, Root Mean Squared Error was 0.4100 and Coefficient of Determination was 0.7733. From the present study, it has been observed that the Ensemble Model is a feasible model to be used for Rainfall, Relative Humidity, and Maximum and Minimum Temperature forecasting

Clinical severity of enteric viruses detected using a quantitative molecular assay compared to conventional assays in the global enteric multicenter study

Background: Quantitative molecular assays are increasingly used for detection of enteric viruses.Methods: We compared the clinical severity using modified Vesikari score (mVS) of enteric viruses detected by conventional assays (enzyme immunoassays [EIA] for rotavirus and adenovirus 40/41 and conventional polymerase chain reaction for astrovirus, sapovirus, and norovirus) and a quantitative molecular assay (TaqMan Array Card [TAC]) among children aged 0-59 months in the Global Enteric Multicenter Study. For rotavirus and adenovirus 40/41, we compared severity between EIA-positive and TAC-positive cases assigned etiologies using different cycle threshold (CT) cutoffs.Results: Using conventional assays, the median (interquartile range) mVS was 10 (8, 11) for rotavirus, 9 (7, 11) for adenovirus 40/41, 8 (6, 10) for astrovirus, sapovirus, and norovirus GII, and 7 (6, 9) for norovirus GI. Compared to rotavirus EIA-positive cases, the median mVS was 2 and 3 points lower for EIA-negative/TAC-positive cases with CT\u3c32.6 and 32.6≤CT\u3c35, respectively (p-value\u3c.0001). Adenovirus 40/41 EIA-positive and EIA-negative/TAC-positive cases were similar, regardless of CT cutoff.Conclusions: Quantitative molecular assays compared to conventional assays, such as EIA, may influence severity of identified cases, especially for rotavirus. Cutoffs to assign etiology for quantitative assays should be considered in the design and interpretation of enteric virus studie

Myalgia‐induced discovery of rhabdomyolysis complicating generalized varicella in an immunocompetent patient: Case report and review of the literature

Key clinical message In a rare occurrence, primary varicella infection led to rhabdomyolysis in a 24‐year‐old with no medical history. Presenting with rash, fever, and weakness, he developed diffuse myalgia at 72 h. Elevated muscle enzymes confirmed rhabdomyolysis secondary to varicella zoster virus (VZV) infection. Treatment with acyclovir and hydration resulted in significant improvement within a month. Abstract Primary varicella infection is rarely complicated by rhabdomyolysis. In this study, we describe a case of rhabdomyolysis complicating a VZV infection in a black subject. The patient was a 24‐year‐old black African with no particular medical history and was immunocompetent. He presented with an acute onset of generalized rash, fever, and generalized weakness. Physical examination revealed vesicular lesions typical of chickenpox. Antipyretic treatment combined with acyclovir was instituted in hospital. At the 72nd hour, diffuse myalgia developed. Muscle enzyme tests revealed CPK elevated to 40 times the upper limit of normal, LDH elevated to 2 times the upper limit of normal, ASAT and ALAT elevated to 7 times the upper limit of normal, and 2.5 times the upper limit of normal, respectively. We accepted the diagnosis of rhabdomyolysis secondary to VZV infection. The patient was given saline hydration and showed clinical and biological improvement 1 month later. A patient presenting with muscular symptoms during a VZV infection should be considered for rhabdomyolysis